So many hot drops leading up to #ESMO26.
Not to be outdone by AZUR-1, CheckMate 8HW, or any of the other incredible IO breakthroughs, Chalabi comes out with the long-term NICHE-2 follow-up.
In a word? Perfect.
111 patients with locally advanced dMMR colon cancer. Just 6 weeks of neoadjuvant nivolumab/ipilimumab followed by surgery.
Zero recurrences. 100% overall survival at 5 years.
And remember, these weren’t all low-risk tumors. Many had high-risk stage III disease.
We’re curing patients with just weeks of immunotherapy.
Now, can we avoid the surgery altogether?
What a time to be treating GI cancers.
@TheGutOncLab @OncoAlert @Onco_Nexus
https://www.sciencedirect.com/science/article/pii/S0140673626016028
3098 浏览 · 57 赞 · 22 转发 · 3 回复
Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity
https://esmocongress.esmo.orgResults from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)
https://esmocongress.esmo.orgFinal pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.orgPrimary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org- A.n.n.@fireflyann
@GIMedOnc I saw Dr @MyriamChalabi slides in 2018.. in Dutch... but could see the word of crc was changing!!!
- Nicholas Hornstein@GIMedOnc
@agrothey Don’t get me started on ATOMIC…
- Axel Grothey@agrothey
@GIMedOnc And move over, ATOMIC!
来源：Nicholas Hornstein · x.com